|
PRESS RELEASE | |
|
|
||
February 4, 2008
Omicron Biochemicals, Inc. and Oligo Factory, Inc. announced an agreement today for the manufacture, sale and distribution of stable isotopically labeled oligodeoxyribonucleotides (DNA oligomers). The companies will offer labeled oligomers with 13C-, 15N-, and/or 2H-labeling that is site and residue specific. In late 2008 the companies plan to offer an equivalent service for oligoribonucleotides (RNA).
The agreement blends the strengths of both companies, with Omicron's expertise in isotope labeling technology and Oligo Factory specializing in milligram to gram scale synthesis and purification of oligonucleotides.
Dr. Anthony Serianni, President and CEO of Omicron, said, "We receive requests regularly for oligonucleotides labeled with stable isotopes but have been unable to offer a comprehensive service until this agreement with Oligo Factory. We are pleased to be able to now satisfy our customers' needs and broaden the basis of our business."
Tim McGrath, CEO of Oligo Factory, concurred and added, "Being able to partner with Omicron Biochemicals, which has a depth of experience in this very specialized market, is a boon to our customers and our business."
About Omicron Biochemicals: Omicron Biochemicals is located in South Bend, Indiana and has been in operation since 1982. The company develops and improves methods to introduce stable isotopes into biologically important compounds. The company specializes in the synthesis of labeled carbohydrates, nucleosides, and their derivatives.
About Oligo Factory: Oligo Factory operates out of its facility in Holliston, MA. The company was formed in 2006 and focuses its efforts on medium scale synthesis and purification of DNA, RNA, chimeras and their modifications.
For more information contact:
Dr. Shikai Zhao – Omicron Biochemicals – 574-287-6910
Web: omicronbio.com
Tim McGrath – Oligo Factory – 508-275-3561
Web: oligofactory.com
Email: info@oligofactory.com